tetano
Editor, Senior Moderator
EClinicalMedicine
. 2022 Mar 12;46:101344.
doi: 10.1016/j.eclinm.2022.101344. eCollection 2022 Apr.
Comparing the longer-term effectiveness of a single dose of the Pfizer-BioNTech and Oxford-AstraZeneca COVID-19 vaccines across the age spectrum
Amit Kaura[SUP] 1 2 [/SUP], Adam Trickey[SUP] 3 [/SUP], Anoop S V Shah[SUP] 1 2 [/SUP], Umberto Benedetto[SUP] 3 4 5 [/SUP], Ben Glampson[SUP] 1 2 [/SUP], Abdulrahim Mulla[SUP] 1 2 [/SUP], Luca Mercuri[SUP] 1 2 [/SUP], Sanjay Gautama[SUP] 2 [/SUP], Ceire E Costelloe[SUP] 1 [/SUP], Ian Goodman[SUP] 6 [/SUP], Julian Redhead[SUP] 2 [/SUP], Kavitha Saravanakumar[SUP] 6 [/SUP], Erik Mayer[SUP] 1 2 [/SUP], Jamil Mayet[SUP] 1 2 [/SUP]
Affiliations
Abstract
Background: A single dose strategy may be adequate to confer population level immunity and protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, especially in low- and middle-income countries where vaccine supply remains limited. We compared the effectiveness of a single dose strategy of the Oxford-AstraZeneca or Pfizer-BioNTech vaccines against SARS-CoV-2 infection across all age groups and over an extended follow-up period.
Methods: Individuals vaccinated in North-West London, UK, with either the first dose of the Oxford-AstraZeneca or Pfizer-BioNTech vaccines between January 12, 2021 and March 09, 2021, were matched to each other by demographic and clinical characteristics. Each vaccinated individual was additionally matched to an unvaccinated control. Study outcomes included SARS-CoV-2 infection of any severity, COVID-19 hospitalisation, COVID-19 death, and all-cause mortality.
Findings: Amongst matched individuals, 63,608 were in each of the vaccine groups and 127,216 were unvaccinated. Between 14 and 84 days of follow-up after matching, there were 534 SARS-CoV-2 infections, 65 COVID-19 hospitalisations, and 190 deaths, of which 29 were categorized as due to COVID-19. The incidence rate ratio (IRR) for SARS-CoV-2 infection was 0.85 (95% confidence interval [CI], 0.69 to 1.05) for Oxford-Astra-Zeneca, and 0.69 (0.55 to 0.86) for Pfizer-BioNTech. The IRR for both vaccines was the same at 0.25 (0.09 to 0.55) and 0.14 (0.02 to 0.58) for reducing COVID-19 hospitalization and COVID-19 mortality, respectively. The IRR for all-cause mortality was 0.25 (0.15 to 0.39) and 0.18 (0.10 to 0.30) for the Oxford-Astra-Zeneca and Pfizer-BioNTech vaccines, respectively. Age was an effect modifier of the association between vaccination and SARS-CoV-2 infection of any severity; lower hazard ratios for increasing age.
Interpretation: A single dose strategy, for both vaccines, was effective at reducing COVID-19 mortality and hospitalization rates. The magnitude of vaccine effectiveness was comparatively lower for SARS-CoV-2 infection, although this was variable across the age range, with higher effectiveness seen with older adults. Our results have important implications for health system planning -especially in low resource settings where vaccine supply remains constrained.
Keywords: Age; COVID-19; Hospitalisation; Mortality; SARS-CoV-2; Vaccination.
. 2022 Mar 12;46:101344.
doi: 10.1016/j.eclinm.2022.101344. eCollection 2022 Apr.
Comparing the longer-term effectiveness of a single dose of the Pfizer-BioNTech and Oxford-AstraZeneca COVID-19 vaccines across the age spectrum
Amit Kaura[SUP] 1 2 [/SUP], Adam Trickey[SUP] 3 [/SUP], Anoop S V Shah[SUP] 1 2 [/SUP], Umberto Benedetto[SUP] 3 4 5 [/SUP], Ben Glampson[SUP] 1 2 [/SUP], Abdulrahim Mulla[SUP] 1 2 [/SUP], Luca Mercuri[SUP] 1 2 [/SUP], Sanjay Gautama[SUP] 2 [/SUP], Ceire E Costelloe[SUP] 1 [/SUP], Ian Goodman[SUP] 6 [/SUP], Julian Redhead[SUP] 2 [/SUP], Kavitha Saravanakumar[SUP] 6 [/SUP], Erik Mayer[SUP] 1 2 [/SUP], Jamil Mayet[SUP] 1 2 [/SUP]
Affiliations
- PMID: 35295900
- PMCID: PMC8918854
- DOI: 10.1016/j.eclinm.2022.101344
Abstract
Background: A single dose strategy may be adequate to confer population level immunity and protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, especially in low- and middle-income countries where vaccine supply remains limited. We compared the effectiveness of a single dose strategy of the Oxford-AstraZeneca or Pfizer-BioNTech vaccines against SARS-CoV-2 infection across all age groups and over an extended follow-up period.
Methods: Individuals vaccinated in North-West London, UK, with either the first dose of the Oxford-AstraZeneca or Pfizer-BioNTech vaccines between January 12, 2021 and March 09, 2021, were matched to each other by demographic and clinical characteristics. Each vaccinated individual was additionally matched to an unvaccinated control. Study outcomes included SARS-CoV-2 infection of any severity, COVID-19 hospitalisation, COVID-19 death, and all-cause mortality.
Findings: Amongst matched individuals, 63,608 were in each of the vaccine groups and 127,216 were unvaccinated. Between 14 and 84 days of follow-up after matching, there were 534 SARS-CoV-2 infections, 65 COVID-19 hospitalisations, and 190 deaths, of which 29 were categorized as due to COVID-19. The incidence rate ratio (IRR) for SARS-CoV-2 infection was 0.85 (95% confidence interval [CI], 0.69 to 1.05) for Oxford-Astra-Zeneca, and 0.69 (0.55 to 0.86) for Pfizer-BioNTech. The IRR for both vaccines was the same at 0.25 (0.09 to 0.55) and 0.14 (0.02 to 0.58) for reducing COVID-19 hospitalization and COVID-19 mortality, respectively. The IRR for all-cause mortality was 0.25 (0.15 to 0.39) and 0.18 (0.10 to 0.30) for the Oxford-Astra-Zeneca and Pfizer-BioNTech vaccines, respectively. Age was an effect modifier of the association between vaccination and SARS-CoV-2 infection of any severity; lower hazard ratios for increasing age.
Interpretation: A single dose strategy, for both vaccines, was effective at reducing COVID-19 mortality and hospitalization rates. The magnitude of vaccine effectiveness was comparatively lower for SARS-CoV-2 infection, although this was variable across the age range, with higher effectiveness seen with older adults. Our results have important implications for health system planning -especially in low resource settings where vaccine supply remains constrained.
Keywords: Age; COVID-19; Hospitalisation; Mortality; SARS-CoV-2; Vaccination.